A woman in her early thirties is told that her anti-Müllerian hormone, or AMH, is “low” and immediately fears that pregnancy is now impossible. Another woman nearing forty is reassured by a “good” AMH and assumes she has plenty of time. Both reactions are understandable. Both can be wrong.

The fertility clock is real, but it is not a countdown display. Age, egg number, egg quality, ovulation, sperm, the fallopian tubes and the uterus all influence conception. AMH measures only one part of that picture.

The subject matters to far more families than fertility clinics suggest: the World Health Organization estimates that about one in six people experience infertility during their lifetime.

Age matters—but 35 is not a trapdoor
Female fertility is highest, on average, in the twenties and early thirties and then declines with age, more noticeably from the mid-thirties onwards. This is a slope, not a switch. There is no biological alarm that rings on a woman’s 35th birthday.

The newest NICE fertility guideline, published in March 2026, gives a useful sense of probability. Among couples having regular intercourse, the estimated cumulative chance of a clinical pregnancy over 12 cycles is about 92% when the woman is 19–26, 87% at 27–29, 86% at 30–34 and 82% at 35–39. Those figures describe populations, not individual guarantees. The decline becomes much more important as women approach forty.

ASRM guidance expresses the same point another way: relative fertility at age 40 is roughly half that of women in their late twenties and early thirties. Age is therefore not destiny, but it remains the strongest single biological predictor of female reproductive potential.

THE NUMBER TO REMEMBER | At 40, relative fertility is roughly half that in the late twenties and early thirties.

You are not losing one egg a month
Women are born with a finite supply of oocytes—the medical term for eggs. Current reproductive-medicine guidance estimates roughly 500,000 to 1 million oocytes at birth. The pool then declines continuously through a natural process called follicular atresia.

Ovulation is not the main reason the egg supply falls. In a typical cycle, a group of follicles—tiny sacs containing immature eggs—begins developing. Usually one ovulates; most of the others stop developing and are reabsorbed, while additional follicles are lost silently in the background.

“Ovarian reserve” therefore refers mainly to the remaining quantity of follicles capable of producing eggs. Women of the same age can have quite different ovarian reserve. Age tells us what tends to happen across a population; ovarian-reserve testing helps describe where an individual may sit within that broad age group.

Egg number and egg quality are different problems
Ovarian reserve is about quantity. Egg quality is about whether an egg can fertilise, form a viable embryo, implant and ultimately result in a live birth.

As oocytes age, the cellular machinery that separates chromosomes during meiosis—the special cell division used to make eggs—becomes more error-prone. This increases the chance of aneuploidy, meaning an egg or embryo has an abnormal number of chromosomes. Many chromosomally abnormal embryos do not implant or miscarry.

That is why advancing maternal age is associated not only with taking longer to conceive, but also with higher miscarriage rates and lower live-birth rates. It also explains a fact that can initially seem contradictory: a 39-year-old may have a high AMH and produce many eggs during IVF, yet age-related egg quality still matters; a 29-year-old with a low AMH may produce fewer eggs but the eggs obtained may, on average, have better chromosomal competence.

What AMH actually measures

AMH is produced mainly by granulosa cells surrounding small growing follicles in the ovaries. Because the number of these follicles broadly reflects the recruitable follicle pool, a blood AMH level is a useful marker of ovarian reserve. AMH is relatively stable across the menstrual cycle and can usually be measured on any day.

Its strongest clinical use is in fertility treatment. AMH, together with the antral follicle count seen on ultrasound, helps predict how the ovaries may respond to stimulation medicines used for IVF: whether relatively few, an average number, or an excessive number of eggs may be retrieved. This helps clinicians plan stimulation and discuss expectations.

AMH is therefore useful for predicting ovarian response. That is not the same as predicting pregnancy.

What AMH cannot tell you

AMH cannot count your remaining eggs one by one or tell you the exact age at which you will become infertile or reach menopause. It says nothing about whether your tubes are open, sperm is healthy, endometriosis is present or the uterine cavity is suitable for implantation.

Most importantly, AMH is not a reliable stand-alone test of natural fertility. ASRM specifically advises that ovarian-reserve markers are poor predictors of current reproductive potential in women without proven infertility, and they add little to prediction of unassisted pregnancy even in many women being evaluated for infertility. A systematic review likewise found no AMH threshold below which live birth becomes impossible after IVF and insufficient evidence to use AMH as a dependable predictor of spontaneous live birth.

A low AMH does not mean “you cannot conceive naturally”. A normal or high result does not mean “you can safely delay pregnancy”.

Why the same AMH number can mean different things
AMH must be interpreted in context, beginning with age. A value that is unremarkable in the early forties may be unexpectedly low in the twenties. Laboratories also use different assays and reference ranges, so one universal internet “normal AMH” range can mislead.

Hormonal contraception can temporarily lower measured AMH, so results need cautious interpretation in women currently using it. AMH may be higher in polyendocrine metabolic ovarian syndrome (PMOS; formerly PCOS), where there are often many small follicles. A high AMH in that setting does not automatically translate into easy natural conception because irregular or absent ovulation may be the real obstacle.

The antral follicle count, or AFC, adds another view: a transvaginal ultrasound counts small follicles visible in both ovaries. AMH and AFC are the most useful ovarian-reserve markers and give broadly comparable information about likely egg yield during stimulation.

Can AMH tell you whether to freeze your eggs?

Not by itself. Planned egg freezing is often marketed as though a blood test can reveal who urgently needs it. That is too simplistic. ASRM advises that decisions about planned oocyte cryopreservation should be based primarily on reproductive plans and age rather than ovarian-reserve testing alone.

Age at freezing matters because freezing preserves eggs at the biological age at which they were collected; it does not rejuvenate them. The HFEA emphasises that the biggest risk of egg freezing is simply that it may not lead to a baby later. A higher AMH may mean more eggs can be collected in one cycle, but it does not cancel the effect of age on egg competence.

For a woman considering fertility preservation, the useful discussion is broader: age now, desired timing and family size, family history of early menopause, ovarian surgery, severe endometriosis or chemotherapy, likely egg yield, and the limitations, costs and risks of treatment.

When should you seek fertility advice?

A common clinical rule is to seek evaluation after 12 months of regular unprotected intercourse if the woman is under 35, and after about six months if she is 35 or older. Women over 40 often benefit from earlier assessment because time has greater biological value. Do not wait for these milestones if periods are very irregular or absent, there is known endometriosis or tubal disease, previous pelvic surgery, recurrent miscarriage, prior chemotherapy or radiotherapy, or a known male-factor problem.

A proper fertility evaluation is couple-based, not an AMH test handed to the woman. It may include ovulation history, semen analysis, ultrasound, tubal assessment and selected hormone tests.

The clock is real. The test is not the clock.

The useful question is not “What is my fertility number?” but “What information changes my decisions?” Age tells us more about average egg quality and reproductive time. AMH and AFC tell us more about egg quantity and likely response to stimulation. Neither can promise pregnancy or declare it impossible.

For women who want children, the best use of this information is not panic. It is planning. A low AMH at 29 should not be treated like infertility by itself, but it may justify a thoughtful conversation about timing. A reassuring AMH at 38 should not be treated like a pause button on ovarian ageing.

The fertility clock does not tick at exactly the same speed for every woman. But no blood test can stop it—and no single number can tell the whole story.

This article provides general health information and is not a substitute for individual medical assessment.

(The author is a consultant obstetrician and gynaecologist based in Bengaluru.)